Results 201 to 210 of about 422,254 (259)

From Provider Judgment to Patient Perspective: Rethinking Functional Class in Pulmonary Hypertension. [PDF]

Chest
Minhas J, Al-Naamani N.
europepmc   +1 more source

Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization

ESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch, Ali Zafari, Shofiqul Islam, Shun Fu Lee, Rajiv Sankaranarayanan, Stephen J Greene, Mamas A Mamas, Ambarish Pandey, Harriette GC Van Spall   +8 more
wiley   +1 more source

Emerging significance of E3 ubiquitin ligases and Deubiquitinases in pulmonary hypertension. [PDF]

Mol Med
Ding CW, Qiu JY, Shen H, Yan Y, Liu ZX, Huang SS, Ma YJ, Jing ZC.   +7 more
europepmc   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Is pulmonary hypertension still a contraindication for lung volume reduction?-a narrative review of contemporary evidence. [PDF]

Ann Transl Med
Adamu Bala M, O'Connor H, Tawalbeh R, Kouritas V.   +3 more
europepmc   +1 more source

Future Prospects of Imatinib in Advanced Pulmonary Hypertension Management. [PDF]

IUBMB Life
Davì F, Mangione S, Iaconis A, Genovese T, Tranchida N, Cuzzocrea S.   +5 more
europepmc   +1 more source

Disproportionate impairment in diffusing capacity predicts pulmonary hypertension with an elevated pulmonary vascular resistance in COPD. [PDF]

Thorax
Balasubramanian A, Hemnes AR, Brittain EL, Annis J, Fawzy A, Putcha N, Singh A, Wise RA, Hansel NN, Simpson C, Kolb TM, Hassoun PM, McCormack MC, Mathai SC.   +13 more
europepmc   +1 more source

Epigenetic Drivers of Pulmonary Hypertension: Environment Meets Genome. [PDF]

Cureus
Whitley WN, Millis RM.
europepmc   +1 more source